$4.440
-0.098 (-2.20%)Al cierre
Comparativa sectorial de GTBP
In the context of the broader market, GTBP competes directly with industry leaders such as MBRX and LEXX. With a market capitalization of $7.99M, it holds a significant position in the sector. When comparing efficiency, GTBP's gross margin of N/A stands against MBRX's N/A and LEXX's 100.00%. Such benchmarking helps identify whether GT Biopharma Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de GT Biopharma Inc
The company reported a widening net loss of approximately $28.4 million for FY2025, up from a $13.2 million loss in FY2024, highlighting ongoing financial struggles. Additionally, the current ratio is low at 2.61, indicating potential liquidity concerns despite some improvement.
Financials
Artículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.